GlassScriptPhysician profile
Reema Patel
NPI 1376801209
$4,510.59
in general payments reported to CMS, 2019-2025
18 companies · $173 in 2025
The $173 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $244 · 2020: $2,506 · 2021: $117 · 2022: $322 · 2023: $582 · 2024: $567 · 2025: $173.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,323.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,322.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Roche Products Limited | $2,275.70 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $412.06 | 2019-2022 | |
| Tempus Ai, INC | $344.79 | 2024 | Xt Cdx |
| Exelixis INC. | $271.26 | 2023 | Cabometyx |
| Astrazeneca Pharmaceuticals LP | $256.15 | 2022-2024 | |
| Abbott Laboratories | $178.96 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Sirtex Medical INC | $153.49 | 2019 | |
| Genentech, INC. | $136.80 | 2023 | Tecentriq, Avastin |
| Genentech USA, INC. | $136.35 | 2020 | |
| Intera Oncology, INC | $123.05 | 2025 | Intera |
| Vertex Pharmaceuticals Incorporated | $102.37 | 2024 | |
| Epizyme, INC. | $85.99 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.96 | 2023 | Fruzaqla |
| Beigene USA, INC. | $13.66 | 2024 | Brukinsa |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reema Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.